Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 503-503 ◽  
Author(s):  
L. Pusztai ◽  
J. Wang ◽  
K. Coombes ◽  
S. Hoersch ◽  
M. Ayers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cdna Arrays ◽  
Affymetrix Genechips ◽  
Predictors Of Response ◽  
Fac Chemotherapy ◽  
Platform Comparison ◽  
Cross Platform

scholarly journals Comparison of the Predictive Accuracy of DNA Array-Based Multigene Classifiers across cDNA Arrays and Affymetrix GeneChips

2005 ◽  
Vol 7 (3) ◽  
pp. 357-367 ◽  
Author(s):  
James Stec ◽  
Jing Wang ◽  
Kevin Coombes ◽  
Mark Ayers ◽  
Sebastian Hoersch ◽  
...  
Keyword(s):  
Predictive Accuracy ◽  
Dna Array ◽  
Cdna Arrays ◽  
Affymetrix Genechips

scholarly journals The role of hormonal ovarian ablation in adjuvant treatment of premenopausal breast cancer

2011 ◽  
Vol 139 (5-6) ◽  
pp. 339-346
Author(s):  
Zafir Murtezani ◽  
Zora Neskovic-Konstantinovic ◽  
Natasa Stanisavljevic ◽  
Vladimir Kovcin
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Steroid Receptors ◽  
Premenopausal Women ◽  
Small Sample ◽  
Malignant Tumours ◽  
Group 13 ◽  
Ovarian Ablation ◽  
Fac Chemotherapy ◽  
Lh Rh

Introduction. Breast cancer is the most frequent malignant disease in women with about 25% compared to all malignant tumours. Chemotherapy, antiestrogen and ovarian ablation/ supression present effective adjuvant approach for premenopausal women diagnosed with hormonal depended, operable breast cancer. Objective. To evaluate benefits of combined chemo/hormonal therapy that is undutiful, but optimal application has not yet been clearly determined. Methods. Thirty-six women were divided into three therapy groups. The first group (13 women) was treated with six cycles of adjuvant FAC chemotherapy followed by regular check-ups; the second group (13 women) after six cycles of adjuvant FAC chemotherapy continued treatment with a two-year application of goserelin given by subcutaneous injections (FAC-Z); the third group (10 women), after six cycles of adjuvant FAC chemotherapy continued with once per month application of gorselin for two years and a daily application of 20 mg tamoxifen for five years (FAC-Z-T). The length of overall disease free period and survival were analyzed in all three groups. Results. The benefit of LH-RH analogues in premenopausal women with hormone-dependent breast cancer was found to be low, and probably limited to smaller subgroups of patients, possibly such as those with either both steroid receptors positive (ER and PR) or those with an extremely high level of steroid receptors. In our paper, analyses of such subgroups could not been performed due to a small sample of patients. The effect of therapy is better in patients, who developed amenorrhoea, regardless of the type of later hormonal therapy. Conclusion. Ovarial ablation, whatever the method, should be probably applied as early as possible within the treatment of early breast cancer, especially in patients in whom chemotherapy induced amenorrhoea is not expected, i.e. in very young female patients.

scholarly journals Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers

Aging ◽  
2021 ◽  
Author(s):  
Dongdong Liu ◽  
Beibei Li ◽  
Xiaoshun Shi ◽  
Jiexia Zhang ◽  
Allen Menglin Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Validation ◽  
Diagnostic Biomarkers ◽  
Cancer Diagnostic ◽  
Cross Platform

scholarly journals Validation Processes of Protein Biomarkers in Serum—A Cross Platform Comparison

Sensors ◽  
2012 ◽  
Vol 12 (9) ◽  
pp. 12710-12728 ◽  
Author(s):  
Katja Köhler ◽  
Harald Seitz
Keyword(s):  
Protein Biomarkers ◽  
Platform Comparison ◽  
Cross Platform
Sign in / Sign up

Export Citation Format

Share Document